In the BioHarmony Drug Report Database
Striverdi Respimat (olodaterol) is a small molecule pharmaceutical. Olodaterol was first approved as Striverdi Respimat on 2014-07-31. It is used to treat chronic bronchitis and pulmonary emphysema in the USA. The pharmaceutical is active against beta-2 adrenergic receptor. Striverdi respimat’s patents are valid until 2030-10-16 (FDA).
Image (chem structure or protein)